Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Inclusion Criteria: * Absolute neutrophil count \>= 1,500/mm3 * No psychiatric illness or social situation that would preclude study compliance * Chemotherapy administered solely as a radiosensitizer or as adjuvant therapy and investigational or targeted therapies (i.e., inhibitors of the epidermal growth factor receptor) will not count toward the maximum of 2 prior regimens allowed * Histologically or cytologically confirmed adenocarcinoma of the intrahepatic or extrahepatic bile duct or gallbladder: * Locally advanced or metastatic disease * At least 1 unidimensionally measurable lesion \>=20 mm by conventional techniques OR \>= 10 mm by spiral CT scan * Not amenable to curative surgical resection * No known brain metastases * Performance status: * ECOG 0-2 * Life expectancy: * More than 12 weeks * Platelet count \>= 100,000/mm3 * WBC \>= 3,000/mm3 * AST and ALT ≤ 2.5 times upper limit of normal (ULN) \[Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels\] * Bilirubin ≤ 1.5 times ULN \[Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels\] * Creatinine within ULN OR Creatinine clearance \>= 60 mL/min * No symptomatic congestive heart failure * No unstable angina pectoris * No symptomatic cardiac arrhythmia within the past 4 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No underlying neuropathy \>= grade …